DH policy documents

National reviews (sexual health)

NCSP plans

Expert Group on chlamydia set up

Expert Group: recommends opportunistic screening
- focus on ♀
- deliver through 1º care

NCSP announced:
To be introduced in Phases

Screening expanded to ♀ & new services

National rollout due, coverage targets set:

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NCSP delivery

Evidence

RCT (USA): "↓ pelvic inflammatory disease (PID)"
Obs (Sweden): "↓ PID & ectopic pregnancy"
RCT (Denmark): "↓ PID"

NICE review (England): biases in early trials may overestimate benefits
Obs (US): screening does not ↓ chlamydia
RCT (England): PID ↓ not significant

National reviews (NCSP)

Diagnoses in women (16-24y):

- GUM only (● =<30,000; ● ● =30,000-40,000; ● ● ● =40,000-50,000; ● ● ● ● =60,000-80,000)
- all tests